Corpus ID: 19621959

Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.

  title={Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.},
  author={Stefania Tommasi and Anita Mangia and Rosanna Lacalamita and Antonia Bellizzi and Vita Fedele and Annalisa Chiriatti and Christoph Thomssen and Nancy Kendzierski and Agnese Latorre and Vito Lorusso and Francesco Schittulli and Francesco Alfredo Zito and Maria Kavallaris and Angelo Paradiso},
  journal={International journal of cancer},
  volume={120 10},
The antineoplastic effect of paclitaxel is mainly related to its ability to bind the beta subunit of tubulin, thus preventing tubulin chain depolarization and inducing apoptosis. The relevance of the Class I beta-tubulin characteristics have also been confirmed in the clinical setting where mutations of paclitaxel-binding site of beta-tubulin Class I have been related to paclitaxel resistance in non small cell lung and ovarian cancers. In the present study, we verified the hypothesis of a… Expand
Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
Data indicate that the effect of class III β-tubulin overexpression may depend on where the drug’s binding site is located on the tubulin, which highlights for the first time the potential key role of targeting the colchicine-binding site, to develop new treatment modalities for taxane-refractory breast cancer. Expand
Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway.
The results demonstrate that the effect of estradiol on beta3-tubulin transcription is mediated through an ER dependent pathway, which is similar to that of other estrogen receptor modulators. Expand
The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin
The results indicate that the expression levels of class III β-tubulin, microtubule-associated protein tau, MAPT, and survivin are good biomarkers for predicting the sensitivity of GC to paclitaxel treatment. Expand
Cancer Cells Acquire Mitotic Drug Resistance Properties Through Beta I-Tubulin Mutations and Alterations in the Expression of Beta-Tubulin Isotypes
This study demonstrated that novel mutations in exon four of the βI-tubulin induced resistance to microtubule de-stabilizers and hyper-sensitivity to micro tubule stabilizer through an alteration in the micro Tubule assembly and dynamics in cancer cells. Expand
End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability
It is shown that the expression of end-binding protein 1 (EB1), a regulator of microtubule dynamics involved in multiple cellular activities, in breast tumor tissues correlates with the pathological response of tumors to paclitaxel-based chemotherapy. Expand
Effect of CH-35, a novel anti-tumor colchicine analogue, on breast cancer cells overexpressing the βIII isotype of tubulin
The toxicity and the anti-tumor activity of one of these compounds, CH-35, was tested on the human breast tumor MDA-MB-231 over-expressing βIII in a xenogeneic mouse model and it was found thatCH-35 was as toxic as Taxol® in vivo. Expand
Markers predicting clinical benefit in breast cancer from microtubule-targeting agents.
  • L. Pusztai
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2007
Large scale pharmacogenomic analysis has identified molecular markers potentially capable of distinguishing patients with differential sensitivity to paclitaxel and ixabepilone, which require validation in clinical trials. Expand
Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition
Non-MDR taxane resistance was associated with reduced intracellular taxane content compared to parental controls, and cross-resistance to other microtubule stabilising drugs, and should be considered as therapeutic targets. Expand
βIII-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cells.
Investigation of the expression and the consequences of βII- and/or βIII-tubulin depletion in interphase microtubule dynamics in non-tumor human mammary epithelial cells finds that both isoforms contribute to the tubulin isotype composition in primary and immortalized human mammaries epithelium cells. Expand
Class III β-tubulin Expression in Colorectal Neoplasms Is a Potential Predictive Biomarker for Paclitaxel Response
Examination of whether βIII-tubulin (TUBB3), present in various types of normal tissues and cancer, is a biomarker for the response of colorectal neoplasms to paclitaxel found it to be expressed in a subgroup of colurctalNeoplasms. Expand